المؤلفون: Huang SJ; Division of Hematology, Vancouver General Hospital, The University of British Columbia, Vancouver, British Columbia, Canada., Gerrie AS; British Columbia Cancer - Vancouver, The University of British Columbia, Vancouver, British Columbia, Canada., Young S; BC Cancer Genetics and Genomics Laboratory, Pathology and Laboratory Medicine, BC Cancer, The University of British Columbia, Vancouver, British Columbia, Canada., Tucker T; BC Cancer Genetics and Genomics Laboratory, Pathology and Laboratory Medicine, BC Cancer, The University of British Columbia, Vancouver, British Columbia, Canada., Bruyère H; Division of Pathology and Laboratory Medicine, Cytogenetics Laboratory, Vancouver General Hospital, The University of British Columbia, Vancouver, British Columbia, Canada., Hrynchak M; Molecular Cytogenetic Laboratory, Royal Columbian Hospital, The University of British Columbia, New Westminster, British Columbia, Canada., Galbraith P; British Columbia Cancer - Abbotsford, The University of British Columbia, Abbotsford, British Columbia, Canada., Al Tourah AJ; British Columbia Cancer - Surrey, The University of British Columbia, Surrey, British Columbia, Canada., Dueck G; British Columbia Cancer - Kelowna, The University of British Columbia, Kelowna, British Columbia, Canada., Noble MC; Royal Columbian Hospital, New Westminster, British Columbia, Canada., Ramadan KM; St. Paul's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada., Tsang P; Division of Hematology, Vancouver General Hospital, The University of British Columbia, Vancouver, British Columbia, Canada; Richmond Hospital, Richmond, British Columbia, Canada., Hardy E; Tom McMurtry & Peter Baerg Cancer Centre, Vernon Jubilee Hospital, British Columbia Cancer, The University of British Columbia, Vernon, British Columbia, Canada., Sehn LH; British Columbia Cancer - Vancouver, The University of British Columbia, Vancouver, British Columbia, Canada., Toze CL; Division of Hematology, Vancouver General Hospital, The University of British Columbia, Vancouver, British Columbia, Canada; British Columbia Cancer - Vancouver, The University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/BMT Program of BC, Vancouver General Hospital, Vancouver, British Columbia, Canada. Electronic address: ctoze@bccancer.bc.ca.

المصدر: Leukemia research [Leuk Res] 2021 Apr; Vol. 103, pp. 106538. Date of Electronic Publication: 2021 Feb 18.

نوع المنشور: Clinical Trial; Comparative Study; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/*mortality, Adenine/administration & dosage ; Adenine/analogs & derivatives ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; British Columbia/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Piperidines/administration & dosage ; Rituximab/administration & dosage ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives

المؤلفون: Huang SJ; Division of Hematology, Vancouver General Hospital, University of British Columbia, Canada., Gerrie AS; Division of Hematology, Vancouver General Hospital, University of British Columbia, Canada; British Columbia Cancer - Vancouver, University of British Columbia, Vancouver, British Columbia, Canada., Young S; Pathology and Laboratory Medicine, British Columbia Cancer, University of British Columbia, Vancouver, British Columbia, Canada., Tucker T; Pathology and Laboratory Medicine, British Columbia Cancer, University of British Columbia, Vancouver, British Columbia, Canada., Bruyere H; Division of Pathology and Laboratory Medicine, Cytogenetics Laboratory, Vancouver General Hospital, University of British Columbia, Canada., Hrynchak M; Molecular Cytogenetic Laboratory, Royal Columbian Hospital, University of British Columbia, New Westminster, British Columbia, Canada., Galbraith P; British Columbia Cancer - Abbotsford, University of British Columbia, Abbotsford, British Columbia, Canada., Al Tourah AJ; British Columbia Cancer - Surrey, University of British Columbia, Surrey, British Columbia, Canada., Dueck G; British Columbia Cancer - Kelowna, University of British Columbia, Kelowna, British Columbia, Canada., Noble MC; Royal Columbian Hospital, New Westminster, British Columbia, Canada., Ramadan KM; St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada., Tsang P; Division of Hematology, Vancouver General Hospital, University of British Columbia, Canada; Richmond Hospital, Richmond, British Columbia, Canada., Hardy E; Tom McMurty & Peter Baerg Cancer Centre, Vernon Jubilee Hospital, Vernon, British Columbia, Canada., Sehn L; British Columbia Cancer - Vancouver, University of British Columbia, Vancouver, British Columbia, Canada., Toze CL; Division of Hematology, Vancouver General Hospital, University of British Columbia, Canada; British Columbia Cancer - Vancouver, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: ctoze@bccancer.bc.ca.

المصدر: Leukemia research [Leuk Res] 2020 Apr; Vol. 91, pp. 106335. Date of Electronic Publication: 2020 Feb 24.

نوع المنشور: Comparative Study; Journal Article

بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Hematopoietic Stem Cell Transplantation/*methods , Leukemia, Lymphocytic, Chronic, B-Cell/*therapy , Pyrazoles/*therapeutic use , Pyrimidines/*therapeutic use , Smith-Magenis Syndrome/*therapy, Adenine/analogs & derivatives ; Adult ; Aged ; Aged, 80 and over ; British Columbia ; Chromosome Deletion ; Chromosomes, Human, Pair 17/genetics ; Cyclophosphamide/therapeutic use ; Disease Management ; Doxorubicin/therapeutic use ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Middle Aged ; Neoplasm, Residual ; Piperidines ; Prednisone/therapeutic use ; Prognosis ; Recurrence ; Remission Induction ; Retrospective Studies ; Rituximab/therapeutic use ; Smith-Magenis Syndrome/diagnosis ; Smith-Magenis Syndrome/genetics ; Smith-Magenis Syndrome/mortality ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/analogs & derivatives ; Vidarabine/therapeutic use ; Vincristine/therapeutic use

SCR Disease Name: Chromosome 17 deletion

SCR Protocol: CHOP protocol; COP protocol 2

المؤلفون: Limvorapitak W; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand., Barnett MJ; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Hogge DE; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Forrest DL; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Nevill TJ; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Narayanan S; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Power MM; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Nantel SH; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Broady R; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Song KW; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Toze CL; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Mourad YA; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Sutherland HJ; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Gerrie AS; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., White J; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Sanford DS; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: david.sanford@bccancer.bc.ca.

المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2018 Nov; Vol. 18 (11), pp. e481-e491. Date of Electronic Publication: 2018 Jul 17.

نوع المنشور: Clinical Trial; Comparative Study; Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Biomarkers, Tumor/*genetics , Consolidation Chemotherapy/*mortality , Karyotyping/*methods , Leukemia, Myeloid, Acute/*mortality , Stem Cell Transplantation/*mortality, Adolescent ; Adult ; Aged ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Gene Expression Regulation, Neoplastic ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Leukemia, Myeloid, Acute/therapy ; Male ; Middle Aged ; Prognosis ; Propensity Score ; Remission Induction ; Retrospective Studies ; Survival Rate ; Transplantation, Autologous ; Transplantation, Homologous ; Young Adult

المؤلفون: Zhu KY; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Song KW; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Connors JM; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Leitch H; Division of Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada., Barnett MJ; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Ramadan K; Division of Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada., Slack GW; Department of Pathology and Laboratory Medicine, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Abou Mourad Y; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Forrest DL; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Hogge DE; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Nantel SH; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Narayanan S; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Nevill TJ; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Power MM; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Sanford DS; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Sutherland HJ; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Tucker T; Genetics Laboratory, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Toze CL; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Sehn LH; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Broady R; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada., Gerrie AS; Hematology, Leukemia/BMT Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada.; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.

المصدر: British journal of haematology [Br J Haematol] 2018 Jun; Vol. 181 (6), pp. 782-790. Date of Electronic Publication: 2018 May 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Burkitt Lymphoma*/drug therapy , Burkitt Lymphoma*/mortality, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Rituximab/*administration & dosage, Adolescent ; Adult ; Aged ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Etoposide/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Ifosfamide/administration & dosage ; Male ; Methotrexate/administration & dosage ; Middle Aged ; Survival Rate ; Time Factors ; Vincristine/administration & dosage

SCR Protocol: ANAVACYM protocol; IVAC protocol

المؤلفون: Lee LJ; a Department of Medicine, Division of Hematology , University of British Columbia , Vancouver , Canada., Toze CL; b Leukemia/BMT Program of BC, Vancouver General Hospital, BC Cancer Agency and University of British Columbia , Vancouver , Canada., Huang SJT; b Leukemia/BMT Program of BC, Vancouver General Hospital, BC Cancer Agency and University of British Columbia , Vancouver , Canada., Gillan TL; c Department of Laboratory Medicine, Medical Genetics Laboratory , Eastern Health , St. John's , Canada., Connors JM; d Centre for Lymphoid Cancer, BC Cancer Agency, University of British Columbia , Vancouver , Canada., Sehn LH; d Centre for Lymphoid Cancer, BC Cancer Agency, University of British Columbia , Vancouver , Canada., Bruyere H; e Department of Pathology and Laboratory Medicine , Vancouver General Hospital, University of British Columbia , Vancouver , Canada., Leitch H; f Division of Hematology , St. Paul's Hospital, University of British Columbia , Vancouver , Canada., Ramadan KM; f Division of Hematology , St. Paul's Hospital, University of British Columbia , Vancouver , Canada., Gerrie AS; b Leukemia/BMT Program of BC, Vancouver General Hospital, BC Cancer Agency and University of British Columbia , Vancouver , Canada.; d Centre for Lymphoid Cancer, BC Cancer Agency, University of British Columbia , Vancouver , Canada.

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2018 Jun; Vol. 59 (6), pp. 1356-1363. Date of Electronic Publication: 2017 Oct 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/*mortality, Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; British Columbia/epidemiology ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology ; Male ; Middle Aged ; Population Surveillance ; Practice Patterns, Physicians' ; Prognosis ; Registries ; Rituximab/administration & dosage ; Survival Analysis ; Treatment Outcome

المؤلفون: Sun H; Division of Hematology, University of British Columbia, Vancouver, Canada., Savage KJ; Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada., Karsan A; Genome Sciences Centre and Department of Pathology, British Columbia Cancer Agency, Vancouver, Canada., Slack GW; Centre for Lymphoid Cancer and Department of Pathology, British Columbia Cancer Agency, Vancouver, Canada., Gascoyne RD; Centre for Lymphoid Cancer and Department of Pathology, British Columbia Cancer Agency, Vancouver, Canada., Toze CL; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Sehn LH; Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada., Abou Mourad Y; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Barnett MJ; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Broady RC; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Connors JM; Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada., Forrest DL; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Gerrie AS; Division of Hematology, University of British Columbia, Vancouver, Canada; Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Hogge DE; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Narayanan S; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Nevill TJ; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Nantel SH; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Power MM; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Sutherland HJ; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Villa D; Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada., Shepherd JD; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Song KW; Division of Hematology, University of British Columbia, Vancouver, Canada; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada. Electronic address: ksong@bccancer.bc.ca.

المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2015 Jun; Vol. 15 (6), pp. 341-8. Date of Electronic Publication: 2015 Jan 03.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

مواضيع طبية MeSH: Gene Rearrangement* , Hematopoietic Stem Cell Transplantation*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Genes, bcl-2/*genetics , Genes, myc/*genetics , Lymphoma, Non-Hodgkin/*genetics , Lymphoma, Non-Hodgkin/*therapy, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Combined Modality Therapy ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Etoposide/administration & dosage ; Female ; Humans ; Ifosfamide/administration & dosage ; Lymphoma, Non-Hodgkin/pathology ; Male ; Methotrexate/administration & dosage ; Middle Aged ; Retrospective Studies ; Rituximab/administration & dosage ; Survival Rate ; Treatment Outcome ; Vincristine/administration & dosage

SCR Protocol: ANAVACYM protocol; IVAC protocol

المؤلفون: Villa D; Princess Margaret Cancer Centre, Toronto, Ontario, Canada; British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Electronic address: dvilla@bccancer.bc.ca., George A; Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia., Seymour JF; Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia., Toze CL; Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, Canada., Crump M; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Lee C; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Buckstein R; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Stewart DA; Tom Baker Cancer Centre, Calgary, Alberta, Canada., MacDonald D; Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada., Foley R; Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada., Xenocostas A; London Health Sciences Centre, London, Ontario, Canada., Sabloff M; The Ottawa Hospital, Ottawa, Ontario, Canada., Chua N; Cross Cancer Institute, Edmonton, Alberta, Canada., Couture F; Hotel Dieu de Quebec, Quebec City, Quebec, Canada., Larouche JF; Hôpital de l'enfant Jesus, Quebec City, Quebec, Canada., Cohen S; Maisonneuve Rosemont Hôpital, Montreal, Quebec, Canada., Savage KJ; British Columbia Cancer Agency, Vancouver, British Columbia, Canada., Connors JM; British Columbia Cancer Agency, Vancouver, British Columbia, Canada., Panzarella T; Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada., Carney DA; Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia., Dickinson M; Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia., Kuruvilla J; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

المصدر: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2014 Nov; Vol. 20 (11), pp. 1813-8. Date of Electronic Publication: 2014 Jul 18.

نوع المنشور: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Carden Jennings Publishing Country of Publication: United States NLM ID: 9600628 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-6536 (Electronic) Linking ISSN: 10838791 NLM ISO Abbreviation: Biol Blood Marrow Transplant Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Hematopoietic Stem Cell Transplantation/*methods , Lymphoma, B-Cell/*therapy, Adult ; Aged ; Anthracyclines/administration & dosage ; Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Cohort Studies ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Humans ; Lymphoma, B-Cell/drug therapy ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Retrospective Studies ; Rituximab ; Survival Rate ; Transplantation Conditioning ; Treatment Outcome

المؤلفون: Abou Mourad YR; Leukemia/BMT Program of BC, British Columbia Cancer Agency, Vancouver General Hospital and University of British Columbia, British Columbia, Canada. Electronic address: ymourad@bccancer.bc.ca., Bhargava R, Bruyère H, Gillian T, Barnett MJ, Forrest DL, Nevill TJ, Toze CL, Nantel SH, Shepherd JD

المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2013 Jun; Vol. 13 (3), pp. 281-6. Date of Electronic Publication: 2012 Oct 24.

نوع المنشور: Case Reports; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

مواضيع طبية MeSH: Chromosome Aberrations*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Fusion Proteins, bcr-abl/*genetics , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*genetics, Adolescent ; Adult ; Aged ; Cohort Studies ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Karyotyping ; Male ; Middle Aged ; Neprilysin/biosynthesis ; Prognosis ; Treatment Outcome ; Young Adult

المؤلفون: Gerrie AS; Division of Hematology, University of British Columbia, Vancouver, BC, Canada. agerrie@bccancer.bc.ca, Toze CL, Ramadan KM, Li CH, Sutherland J, Yee A, Connors JM

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2012 Jan; Vol. 53 (1), pp. 77-82. Date of Electronic Publication: 2011 Sep 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy, Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Antibodies, Monoclonal, Murine-Derived/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; British Columbia ; Clinical Trials as Topic/methods ; Clinical Trials as Topic/standards ; Drug Administration Schedule ; Fatigue/chemically induced ; Female ; Follow-Up Studies ; Humans ; Male ; Rituximab ; Survival Analysis ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; Vidarabine/analogs & derivatives

المؤلفون: Venner CP; The Vancouver Hospital and Health Science Center, British Columbia, Canada., Connors JM, Sutherland HJ, Shepherd JD, Hamata L, Mourad YA, Barnett MJ, Broady R, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Nitta J, Power MM, Toze CL, Smith CA, Song KW

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2011 Jan; Vol. 52 (1), pp. 34-41. Date of Electronic Publication: 2010 Dec 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Multiple Myeloma/*mortality , Multiple Myeloma/*therapy , Neoplasm Recurrence, Local/*mortality , Neoplasm Recurrence, Local/*therapy, Adult ; Aged ; Boronic Acids/administration & dosage ; Bortezomib ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Lenalidomide ; Male ; Middle Aged ; Multiple Myeloma/pathology ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Pyrazines/administration & dosage ; Risk Factors ; Survival Rate ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives ; Transplantation, Autologous ; Young Adult